Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... (

Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ...

- Both co-primary endpoints, Wake After Sleep Onset and Total Sleep Time, and key secondary endpoints, including Latency to Persistent Sleep, were met at both doses - Evotec to host a conference call at 4pm CET (3pm UK time, 10am EST) today

HAMBURG, Germany | OXFORD, England, June 4, 2007-- Evotec AG (Frankfurt Stock Exchange: EVT) announced today positive top-line results from its first phase II clinical trial of EVT 201 in patients with chronic primary insomnia. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. The double-blinded, placebo controlled cross-over study design of two doses of EVT 201 (1.5mg and 2.5mg) in 67 patients was conducted in sleep labs in the US using objective polysomnography. The pre-specified intention-to-treat analysis of the study showed statistically highly significant improvements between both doses of EVT 201 and placebo in both of the co-primary endpoints of Total Sleep Time (TST) (p<0.001) and Wake After Sleep Onset (WASO) (p<0.001). Notably, WASO during the second half of the night was also significantly (p<0.001) reduced, indicating that EVT 201 has efficacy in sleep maintenance throughout the night.

Improvements were also seen across pre-specified secondary endpoints. Latency to persistent sleep was markedly decreased by both doses of EVT 201 (p<0.001) and patients reported highly significant improvements in subjectively assessed quality of sleep (p<0.001 both doses). Treatment with EVT 201 was completely without effect on subjectively assessed residual sedation the next day and produced only a small decremental effect on the digital symbol substitution test (DSST) assessed at nine hours post dosing. Initial analysis showed that EVT 201 did not impair slow wave sleep unlike many benzodiazepine full agonists. The study therefore demonstrated EVT 201 has robust effects on both sleep onset and sleep maintenance and is without
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

Post Your Comments:

( - Both co-primary endpoints Wake Afte...)Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ...,Health